Sarepta Therapeutics (SRPT) Capital Expenditures (2010 - 2026)

Sarepta Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 95.23% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $60.4 million (down 59.23% YoY), while the FY2025 annual figure was $102.0 million, down 25.54% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2.1 million, down from $3.6 million in the prior quarter.
• The five-year high for Capital Expenditures was $43.7 million in Q1 2025, with the low at $2.1 million in Q1 2026.
• The 5-year median for Capital Expenditures is $19.0 million (2023), against an average of $20.5 million.
• The sharpest annual moves came in 2022 and 2026: Capital Expenditures surged 261.02% in 2022, then slumped 95.23% in 2026.
• Sarepta Therapeutics' Capital Expenditures stood at $8.0 million in 2022, then soared by 139.06% to $19.0 million in 2023, then soared by 100.02% to $38.1 million in 2024, then tumbled by 90.57% to $3.6 million in 2025, then slumped by 42.05% to $2.1 million in 2026.
• Business Quant data shows SRPT's Capital Expenditures at $2.1 million in Q1 2026, $3.6 million in Q4 2025, and $22.9 million in Q3 2025.